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This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based 
research. The summary is not intended to be a comprehensive summary of available evidence on 
COVID-19 but aims to make original documents easily accessible to decision makers which, if 
relevant to them, they should go to before making decisions. 
Epidemiology and modelling  
Publication 
date 
Title/URL Journal/Articl
e type 
Summary Keywords 
13.11.2020 Seroprevalence 
of SARS-CoV-2 in 
slums versus 
non-slums in 
Mumbai, India 
The Lancet 
Global Health 
| 
Corresponde
nce 
• Estimating 
seroprevalence 
is crucial for 
controlling the 
transmission of 
SARS-CoV-2 
• This study 
estimated 
prevalence in six 
slums and non-
slum 
communities 
across 3 wards 
of Mumbai, India 
– socioeconomic 
disparities and 
population 
density might 
drive disease 
dynamics in 
megacities 
• Estimates 
suggest a higher 
prevalence in 
slums which 
could be driven 
by population 
density, lower 
adherence to 
Seroprevalence, 
India, slums 
distancing 
measures and 
poorer hygiene 
• Mapping 
estimates to 
locations 
showed sharp 
differences over 
distances as 
little as 100 m 
11.11.2020 Seroprevalence 
of anti-SARS-
CoV-2 IgG 
antibodies in 
Kenyan blood 
donors 
Science | 
Report 
• A national and 
regional 
estimate of 
population 
exposure to 
SARS-CoV-2 in 
an African 
country 
• This study 
determined the 
prevalence of 
anti-SARS-CoV-
2 IgG antibodies 
among blood 
donors in Kenya 
in April-June 
2020 
• Crude 
seroprevalence 
was 5.6%  
• Population-
weighted, test-
performance-
adjusted national 
seroprevalence 
was 4.3% and 
highest in urban 
counties 
Mombasa 
(8.0%), Nairobi 
(7.3%) and 
Kisumu (5.5%) 
• SARS-CoV-2 
exposure is 
more extensive 
than suggested 
by case-based 
surveillance 
Seroprevalence, 
Kenya 
11.11.2020 Cost-
effectiveness of 
public-health 
strategies for 
COVID-19 
epidemic control 
The Lancet 
Global Health 
| Article 
• Development of 
a dynamic 
microsimulation 
model to assess 
clinical and 
economic 
outcomes and 
Cost 
effectiveness, 
public health 
strategies, South 
Africa 
in South African: 
a microsimulation 
modelling study 
cost-
effectiveness of 
epidemic control 
strategies in 
KwaZulu-Natal 
province, South 
Africa 
• Difference 
combinations of 
five public health 
interventions 
were compared 
• In South Africa, 
strategies 
combining 
household 
contact tracing, 
isolation of 
individuals with 
COVID-19, mass 
symptom 
screening, and 
quarantining 
household 
contacts of 
COVID-19 cases 
would 
substantially 
reduce COVID-
19 mortality and 
would be cost-
effective 
• Optimal 
combination of 
interventions 
depends on 
epidemic growth 
characteristics 
and practical 
implementation 
considerations 
11.11.2020 Persistence and 
Evolution of 
SARS-CoV-2 in 
an 
immunocompromi
sed host 
NEJM | 
Corresponde
nce 
• Although most 
immunocompro
mised persons 
effectively clear 
SARS-CoV-2 
infection, this 
case highlights 
the potential for 
persistence and 
accelerated 
SARS-CoV-2 
evolution 
associated with 
an 
SARS-CoV-2, 
immunocompromi
sed host 
immunocompro
mised host 
• Suggests that 
combination 
antiviral therapy 
is likely needed 
Infection Prevention and Control 
Publication 
date 
Title/URL Journal/Article 
type 
Summary Keywords 
13.11.2020 Combatting 
the COVID-
19 
pandemic 
in a 
resource-
constrained 
setting: 
insights 
from initial 
response in 
India 
BMJ Global 
Health | 
Practice 
• Analysis of India’s response 
to the pandemic (17 Jan to 20 
April 2020) 
• India leveraged existing legal 
frameworks, institutional 
mechanisms and 
administrative provisions to 
respond to the pandemic but 
the cross-sectoral impact of 
the initial combat was intense 
and is potentially long-lasting 
authors warn 
• Authors suggest that the 
country could have further 
benefitted from evidence-
based policy and planning in-
line with local needs and 
vulnerabilities 
• The pandemic response in 
India is complex given 
variegated epidemiological, 
socio-political and systemic 
vulnerabilities 
• Authors suggest that learning 
from India’s initial response 
will help in response 
preparedness and planning 
for future pandemics, 
especially in the LMIC 
context, and in the need to 
have contextualised 
pandemic response plans 
India, 
pandemic 
response, 
context 
  
Testing 
Publication 
date 
Title/URL Journal/Article 
type 
Summary Keywords 
11.11.2020 Accuracy 
of UK 
rapid test 
consortium 
(UK-RTC) 
“AbC-19 
Rapid 
Test” for 
detection 
of previous 
SARS-
CoV-2 
infection in 
key 
workers: 
test 
accuracy 
study 
BMJ | Article 
• UK test accuracy study of the 
AbC-19 Rapid Test lateral flow 
immunoassay for the detection 
of previous SARS-CoV-2 
infection in 2847 key workers 
• Test sensitivity was lower 
among unselected populations 
than among PCR confirmed 
cases of SARS-CoV-2 
Test 
accuracy 
Therapeutics 
Publication 
date 
Title/URL Journal/Article 
type 
Summary             Keywords 
12.11.2020 Safety and 
efficacy of 
inhaled 
nebulised 
interferon 
beta-1a 
(SNG001) for 
treatment of 
SARS-CoV-2 
infection: a 
randomised, 
double-blind, 
placebo-
controlled, 
phase 2 trial 
Lancet 
Respiratory 
Medicine | 
Article 
• Randomised, double-
blind, placebo controlled, 
phase 2 pilot trial at 9 
UK sites to assess the 
efficacy and safety of 
inhaled nebulised 
interferon beta-1a 
(SNG001) for the 
treatment of adults aged 
18 years or older 
admitted to hospital with 
COVID-19 
• Patients who received 
SNG001 had greater 
odds of improvement 
and recovered more 
rapidly from SARS-CoV-
2 infection than patients 
who received placebo  
Interferon 
beta-1a, 
SNG001 
• SNG001 was well 
tolerated compared with 
placebo 
• This proof of concept 
trial provides strong 
rationale for further 
larger trials 
12.11.2020 Fluvoxamine 
vs placebo 
and clinical 
deterioration 
in outpatients 
with 
symptomatic 
COVID-19: a 
randomized 
clinical trial 
JAMA | 
Preliminary 
Communication 
• Adult outpatients with 
symptomatic COVID-19 
treated with fluvoxamine, 
compared with placebo, 
had a lower likelihood of 
clinical deterioration over 
15 days 
• This is a preliminary 
study, larger randomised 
trials with more definitive 
outcome measures 
would be required to 
determine clinical 
efficacy 
Fluvoxamine 
Vaccines 
Publication 
date 
Title/URL Journal/Article 
type 
Summary Keywords 
   
• Refer to Comments, Editorials, 
Opinions, Blogs, News Section 
below for press release on 
Moderna vaccine 
 
Comments, Editorials, Opinions, Blogs, News 
Publication 
date 
Title/URL Journal | Article type 
16.11.2020 Moderna announces longer shelf 
life for its COVID-19 vaccine 
candidate at refrigerated 
temperatures 
Moderna | Press release 
16.11.2020 Moderna’s COVID-19 vaccine 
candidate meets it primary efficacy 
endpoint in the first interim analysis 
of the phase 4 COVE study  
Moderna | Press release 
16.11.2020 Teenage pregnancies rise in parts 
of Kenya as lockdown shuts 
schools 
Reuters | News 
13.11.2020 Hydroxychloroquine and COVID-
19: a tale of populism and 
obscurantism 
The Lancet Infectious Diseases 
13.11.2020 Provision of holistic care after 
severe COVID-19 pneumonia: 
anticipating clinical need and 
managing resources 
Lancet Respiratory Medicine | Spotlight 
13.11.2020 COVID mink analysis shows 
mutations are not dangerous - yet 
Nature | News 
12.11.2020 Nebulised interferon beta-1a for 
patients with COVID-19 
Lancet Respiratory Medicine | Comment 
12.11.2020 Beyond the rhetoric of equity: will 
the frontline healthcare workers 
who serve the poor be prioritized 
for the COVID vaccine? 
CGD | Blog 
12.11.2020 Strong health care systems are key 
to deliver COVID-19 vaccines 
World Bank | Blog 
11.11.2020 Are asylum seekers, refugees and 
foreign migrants considered in the 
COVID-19 vaccine discourse? 
BMJ Global Health | Commentary 
11.11.2020 Leveraging the COVID-19 
response to end preventable child 
deaths from pneumonia 
The Lancet | Comment 
10.11.2020 Turning the tide: the fight to reclaim 
gains and accelerate progress for 
women and children 
World Bank | Blog 
10.11.2020 Don’t cheer yet – there is too much 
at stake on COVID-19 vaccines 
CGD | Blog 
10.11.2020 The great coronavirus pandemic of 
2020-7 critical lessons 
JAMA | Forum 
09.11.2020 Monday morning vaccine 
breakthrough: terrific news for the 
west, but in LMICs terms and 
conditions apply 
CGD | Blog 
09.11.2020 Misguided use of 
hydroxychloroquine for COVID-19 
JAMA | Editorial 
09.11.2020 ‘I’ve never worked harder’: the race 
to develop a COVID-19 vaccine 
Nature | Where I work 
Guidelines, Statements & Tools 
 Publication 
Date 
Title/URL Source   Summary 
13.11.2020 Statement on 
COVID-19 and the 
training of 
healthcare 
professionals in 
Africa 
Africa 
CDC 
• Africa CDC recommendations for the 
training of healthcare professionals in 
higher institutions in Africa 
 
   
 
Dashboards & Trackers 
Cases & deaths: 
Global 
Cases & 
deaths: 
Regional 
Cases & 
deaths: 
Country 
Living evidence & 
policy maps 
Current research 
including trials 
  Diagnostics   Treatments   Vaccines 
WHO sitreps  WHO Africa  Ghana  COVID-NMA  WHO    FIND SARS-
CoV-2 Test 
Tracker 
  Global COVID-
19 Clinical Trial 
Tracker 
  CEPI 
WHO dashboard  African 
Arguments  
Indonesia  EPPI Centre  WHO International 
Clinical Trials 
Registry Platform 
(ICTRP)  
 FIND SARS-
CoV-2 
Diagnostics: 
performance 
data 
  US NIH 
registered 
clinical trials 
Vaccine 
Centre LSHTM  
Johns Hopkins 
University  
European 
CDC  
Nigeria CDC  Norwegian 
Institute of Public 
Health  
Cytel   Serology-based 
tests for COVID-
19 
  Solidarity trial  COVID-19 
Oxford 
Vaccine Trial 
WEF    Sierra Leone   Oxford C19 
Government 
Response 
Tracker 
(OxCGRT) 
US NIH   Our World in 
Data: C19 
Testing 
  COVID-19 
Therapeutics 
Accelerator 
 COVID-19 
Vaccine 
Tracker 
Our World in 
Data  
  Singapore   Our World in 
Data: C19 Policy 
responses 
COVID-evidence        
Global 5050    UK   IFPRI COVID-19 
Policy Response 
Portal 
Cochrane        
CEBM, University 
of Oxford  
  US   COVID-19 
Primer 
Clinicaltrials.gov        
Humanitarian 
Data Exchange  
     NIH LitCovid  UKCDR       
Information is 
Beautiful  
     WHO COVID-19 
Database 
        
LSHTM                
HealthMap 
(cases) 
              
The Commons 
Project 
              
SeroTracker                
  
   
 
C19 Resource Hubs 
Global  Regional 
& Country 
Academi
c 
journals 
& 
Publisher
s 
Institutes/Centres/Funders/
Other 
Health 
Topics 
  Social 
Sciences 
WHO 
COVID-19 
pandemic  
Africa 
CDC 
Annals of 
Internal 
Medicine 
LSTM Stop TB 
Partnership 
  SSHAP 
WHO risk 
communicati
on 
African 
Union 
BMJ LSHTM 
 
  IDA 
WHO Q&A Nigeria 
CDC 
Bulletin 
of the 
WHO 
ICL MRC Centre for Global 
Infectious Disease Analysis  
Global 
Menstrual 
Collective  
  Disability 
and 
inclusion 
WHO Global 
research 
GeoPoll: 
SSA 
Cambrid
ge 
Universit
y Press 
ODI SLH: 
Handwashi
ng in low 
resource 
settings 
  Coregrou
p IDDC 
COVID-19 
Solidarity 
Response 
Fund 
Global 
Health 
Network 
Africa 
Cell 
Press 
Johns Hopkins University RBM 
Partnership 
  Ethics, 
health 
systems & 
COVID-19 
UN African 
Academy 
of 
Sciences 
Cochran
e  
Center for Global 
Development 
 Epidemic 
Preparedne
ss 
Innovations 
  Social 
Developm
ent Direct 
C19 blog 
series 
UN Women Africa 
Evidence 
Network 
Elsevier CMMID Repository     
UNOCHA OCHA 
Southern 
and 
Eastern 
Africa 
COVID-19 
Digest 
Health 
Policy 
and 
Planning  
Norwegian Institute of 
Public Health 
    
UNHCR  South 
African 
Governme
nt 
JAMA 
Network 
Oxford Centre for 
Evidence-based Medicine 
    
UNICEF   The 
Lancet 
 HEART     
UNESCO   medRxiv 
and 
bioRxiv 
(Preprint
s) 
 UKRI     
UN WFP   NEJM  Evidence Aid     
GOARN   Oxford 
Universit
y Press 
 NIH     
EPI-WIN   PLoS IFPRI Resources and 
Analyses of C19 Impact 
    
World Bank   SAGE 
journals 
 Prevent Epidemics      
Our World in 
Data 
  Science       
COVID-19 
Narratives by 
David 
Nabarro 
  Springer 
Nature 
      
Reliefweb   SSRN 
(Preprint
s)  
      
Humanitarian 
OpenStreetM
ap Team 
  Wiley       
Global 
Partnership 
for 
Sustainable 
Development 
Data 
  
 
      
WorldPop           
Flowminder           
COVID-END           
Premise 
COVID-19 
Global 
Impact Study 
    
  
GISAID           
Online learning & events 
 Date Title/URL Online 
learning/event 
Duration Lead 
19.11.2020 Looking at the 
pandemic with a 
gender lens 
Live Twitter 
conversation 
  SSHAP 
16.11.2020 HIFA and WHO 
collaborate to 
promote sharing of 
experience and 
4-week 
discussion 
starting 16 Nov 
  HIFA 
expertise around the 
maintenance of 
essential health 
services during (and 
after) the pandemic 
10.11.2020 COVID-19 vaccine 
predictions part 2: 
estimating the time 
before we approve 
efficacious COVID-19 
vaccines 
Online event 1h30 CGD 
16.10.2020 Financing a Global 
Public Health 
Response 
Online event 1h30 CGD 
02.10.2020 Understanding and 
Improving COVID-19 
Vaccine Portfolio 
Online event 1h30 CGD 
21.09.2020 Mitigating the 
Economic and Health 
Impact of COVID-19 
across Africa 
Online event 1h30 CGD, GF, AU 
June 2020 OpenWHO, the free, 
open-access learning 
platform for health 
emergencies, now 
offers 10 online 
courses related to 
COVID19. 
Online courses Varies WHO 
Available 
now 
Standard 
precautions: 
Environmental 
cleaning and 
disinfection 
Online course 1 hour WHO 
Available 
now 
COVID-19: Effective 
Nursing in Times of 
Crisis 
Online course 2 weeks – 
2 hours 
per week 
Johns Hopkins School 
of Nursing 
Available 
now 
WHO Academy and 
WHO Info mobile 
applications 
Mobile app   WHO 
Available 
now 
COVID-19: 
Pandemics, 
Modelling and Policy 
Online learning 2 weeks | 
2 hours 
weekly 
study 
FutureLearn UNESCO 
UNITWIN Complex 
Systems Digital 
Campus/Open 
University 
11.5.2020 COVID-19 Contact 
Tracing course 
Online learning 5 hours Johns Hopkins 
Bloomberg School of 
Health 
7-28 May 
2020 
Virtual Evidence 
Weeks 
5 sessions 1h 30 International Initiative 
for Impact Evaluation 
(3ie) 
Tuesdays 
at 1700 
CEST 
(Geneva 
time) & 
Thursdays 
0830 CEST 
(Geneva 
time) 
COVID-19 Open 
online brief with Dr 
David Nabarro 
Event 1h 4SD 
Available 
now 
Emerging respiratory 
viruses, including 
COVID-19: methods 
for detection, 
prevention, response 
and control 
Online learning 3 hours WHO 
Available 
now 
Responding to 
COVID-19: Real-time 
training for the 
coronavirus disease 
outbreak 
Online learning Multiple 
self-paced 
course 
WHO 
25 May 
2020 
COVID-19: Tackling 
the Novel 
Coronavirus 
Online learning 3 weeks | 
4 hours 
weekly 
study 
FutureLearn 
LSHTM/UK PHRST 
Available 
online now 
without 
mentors. 
Updated 
version will 
commence 
early June 
2020 
COVID-19 
Diagnostics and 
Testing 
Online learning 3 weeks | 
3 hours 
weekly 
study 
FutureLearn 
FIND/LSHTM/ASLM 
6 April 2020 COVID-19 Critical 
Care: Understanding 
and Application 
Online learning 5 weeks | 
1 hour 
weekly 
study 
FutureLearn University 
of Edinburgh & Royal 
College of Physicians 
of Edinburgh  
Available 
now 
COVID-19 supporting 
online courses 
Online learning Multiple 
self-paced 
course 
BMJ Learning 
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Rapid review methodology 
The rapid weekly search for peer-reviewed literature is carried out through a PubMed search with the following 
keywords (“COVID-19” OR “severe acute respiratory syndrome coronavirus 2” OR “2019-nCoV” OR “SARS-CoV-
2” OR “2019nCoV” OR “coronavirus” ) AND (“Africa” OR “South Asia” OR “Developing” OR “low-income” OR “low 
income” OR “lower-middle income” OR “low and middle income” OR “LMIC” OR “LIC” OR “global south”) OR 
(“poverty”) OR (“equity” OR “equities”), restricted to articles published in the previous 2 to 3 days, in English. This 
is complemented by a search of the homepage of the following high-impact global health journals: The Lancet 
journals, New England Journal of Medicine, Nature, JAMA, Annals of Internal Medicine, Cochrane Reviews, BMJ 
Global Health, the PLoS journals and a Twitter search of their Twitter pages. A search also of preprints from bioRxiv 
and medRxiv. Please note that papers that have not been peer-reviewed are highlighted in red. All primary research 
papers that relate to the primary and secondary impacts of the COVID-19 response in LMICs, and disease control 
and health system responses are included. Articles related to tackling the secondary impacts on other sectors are 
not included. Additional commentaries, opinions, and commissioned pieces are selected based on relevance. 
 The search for dashboards, guidelines, tools, editorials, comments, blogs, opinions and news is through the 
academic journals listed above, C19 resource hubs and following lead academics and professionals on Twitter. 
 
About this report  
This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based research. The 
summary is not intended to be a comprehensive summary of available evidence on COVID-19 but aims to make 
original documents easily accessible to decision makers which, if relevant to them, they should go to before making 
decisions. The HES are not intended to replace medical or professional advice and the researcher or the K4D 
consortium cannot be held responsible for any decisions made about COVID-19 on the basis of the HES alone. 
K4D services are provided by a consortium of leading organisations working in international development, led by 
the Institute of Development Studies (IDS), with Education Development Trust, Itad, University of Leeds Nuffield 
Centre for International Health and Development, Liverpool School of Tropical Medicine (LSTM), University of 
Birmingham International Development Department (IDD) and the University of Manchester Humanitarian and 
Conflict Response Institute (HCRI). 
This evidence summary was prepared for the UK Government’s Foreign, Commonwealth 
and Development Office (FCDO) and its partners in support of pro-poor programmes. Except 
where otherwise stated, it is licensed for non-commercial purposes under the terms of the 
Open Government Licence v3.0. K4D cannot be held responsible for errors, omissions or 
any consequences arising from the use of information contained in this health evidence 
summary. Any views and opinions expressed do not necessarily reflect those of FCDO, K4D 
or any other contributing organisation.  
© Crown copyright 2020. 
